Title:
AST-3424 COMBINATION FOR TREATING LEUKEMIA AND LYMPHOMA
Document Type and Number:
WIPO Patent Application WO/2024/051792
Kind Code:
A1
Abstract:
A treatment method, comprising using a drug containing AST-3424, AST-3423 or AST-2870 and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof in combination with a drug containing cytarabine or daunorubicin and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof to treat leukemia and lymphoma patients. Where the concentration of daunorubicin or cytarabine is far lower than the clinical dosage thereof, there is no need to limit patients to those with higher (overexpression, excess) AKR1C3 protein or RNA expression; the combination of AST-3424 and cytarabine or daunorubicin still has a remarkable inhibitory effect on the in-vitro proliferation of leukemia or lymphoma cells, and the combination has a relatively good inhibitory effect on the in-vitro proliferation of cell lines with different levels of AKR1C3 protein or RNA expression. Therefore, the described combination protocol is expected to be developed into a new treatment protocol for treating leukemia and lymphoma without limiting the level of AKR1C3 enzyme expression in patients.
Inventors:
XIE YANBIN (CN)
HAO JING (CN)
QI TIANYANG (CN)
MENG FANYING (US)
DUAN JIANXIN (CN)
HAO JING (CN)
QI TIANYANG (CN)
MENG FANYING (US)
DUAN JIANXIN (CN)
Application Number:
PCT/CN2023/117606
Publication Date:
March 14, 2024
Filing Date:
September 08, 2023
Export Citation:
Assignee:
ASCENTAWITS PHARMACEUTICALS LTD (CN)
International Classes:
A61K31/04; A61K31/7068; A61P35/02
Domestic Patent References:
| WO2022231580A1 | 2022-11-03 | |||
| WO2022178821A1 | 2022-09-01 | |||
| WO2019062919A1 | 2019-04-04 | |||
| WO2021110085A1 | 2021-06-10 |
Foreign References:
| TW202241455A | 2022-11-01 | |||
| CN112004799A | 2020-11-27 | |||
| CN108290911A | 2018-07-17 | |||
| CN112961916A | 2021-06-15 |
Other References:
VERMA KSHITIJ, ZANG TIANZHU, PENNING TREVOR M., TRIPPIER PAUL C.: "Potent and Highly Selective Aldo–Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 62, no. 7, 11 April 2019 (2019-04-11), US , pages 3590 - 3616, XP093142648, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00090
Attorney, Agent or Firm:
SHANGHAI DANRONG & ZONGDE INTELLECTUAL PROPERTY AGENCY CO., LTD. (CN)
Download PDF:
Previous Patent: COMMUNICATION METHODS AND RELATED APPARATUS
Next Patent: METHODS ANS KITS FOR TREATING SARS-CoV-2 INFECTION
Next Patent: METHODS ANS KITS FOR TREATING SARS-CoV-2 INFECTION